Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/18/2010WO2010034838A3 Antiproliferative compounds
11/18/2010WO2010033426A3 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
11/18/2010WO2010014814A8 Glycosylated warfarin analogs and uses thereof
11/18/2010WO2009156735A3 New therapeutic agents
11/18/2010WO2009141079A8 Novel [f-18]-labelled l-glutamic acid and l-glutamine derivatives (ii), use thereof and method for their production
11/18/2010US20100292791 Fully synthetic implantable multi-phased scaffold
11/18/2010US20100292456 Rna interference mediating small rna molecules
11/18/2010US20100292348 Detection of methylated dna and dna mutations
11/18/2010US20100292345 Therapeutic uses of cannabigerol
11/18/2010US20100292342 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
11/18/2010US20100292331 Biomarkers for Prostate Cancer and Methods Using the Same
11/18/2010US20100292322 Bis-Platinum Complexes With Antitumor Activity
11/18/2010US20100292320 Benzofuran anilide histone deacetylase inhibitors
11/18/2010US20100292316 Improved therapeutic methods and compositions comprising chroman ring compounds
11/18/2010US20100292314 Anti-angiogenic compositions and methods of use
11/18/2010US20100292312 Anti-dll4 antibodies and methods using same
11/18/2010US20100292311 Oligomeric compounds for the modulation of survivin expression
11/18/2010US20100292309 Inducing immune-mediated tumor cell death
11/18/2010US20100292308 Microrna molecules
11/18/2010US20100292303 Gene expression profile for predicting ovarian cancer patient survival
11/18/2010US20100292302 Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
11/18/2010US20100292300 Compositions and methods for inhibiting or reversing fibrotic disorders
11/18/2010US20100292296 Novel ligands that modulate rar receptors
11/18/2010US20100292284 Talarazole metabolites
11/18/2010US20100292283 Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators
11/18/2010US20100292279 Bis-(Sulfonylamino) Derivatives in Therapy
11/18/2010US20100292272 Supramolecular co-colloids produced using macrocyclic polyanionic systems
11/18/2010US20100292266 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase
11/18/2010US20100292262 4 (pyrrolo[2,3-c]pyridine-3-yl)pyrimidin-2-amine derivatives
11/18/2010US20100292255 Therapeutic Compounds and Their Use in Treating Diseases and Disorders
11/18/2010US20100292252 Vinyl-aryl derivatives for inflammation and immune-related uses
11/18/2010US20100292247 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
11/18/2010US20100292244 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
11/18/2010US20100292240 Sulfonamide compounds
11/18/2010US20100292235 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/18/2010US20100292234 Triazole fused heteroaryl compounds and methods of use thereof
11/18/2010US20100292233 Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
11/18/2010US20100292231 Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers
11/18/2010US20100292229 Tryphostin-analogs for the treatment of cell proliferative diseases
11/18/2010US20100292222 Chemical compounds 751
11/18/2010US20100292218 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives
11/18/2010US20100292208 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
11/18/2010US20100292207 Substituted indazole derivatives active as kinase inhibitors
11/18/2010US20100292205 Pyrimidone Compounds As GSK-3 Inhibitors
11/18/2010US20100292204 Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
11/18/2010US20100292197 Compositions and Methods for Increasing Telomerase Activity
11/18/2010US20100292196 Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
11/18/2010US20100292195 Low burst polymers and methods to produce polymer
11/18/2010US20100292193 Radioprotective drugs
11/18/2010US20100292190 Novel tubulin polymerisation inhibitors
11/18/2010US20100292186 Pharmaceutical Composition for Treatment or Prevention of Liver Cancer
11/18/2010US20100292177 Methods of treatment using combination therapy
11/18/2010US20100292176 Antitumor agent
11/18/2010US20100292169 Methods and compositions for regulating hdac6 activity
11/18/2010US20100292167 C-met kinase binding proteins
11/18/2010US20100292166 PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMORS CONTAINING HUMAN p31 GENES
11/18/2010US20100292164 Dimerized peptide
11/18/2010US20100292163 Antitumoral Compounds
11/18/2010US20100292162 Socs-3 promoter methylation in cancer
11/18/2010US20100292161 Polypeptides and methods of use
11/18/2010US20100292160 Hla-a* 3303-restricted wt1 peptide and pharmaceutical composition comprising the same
11/18/2010US20100292148 Targeted polylysine dendrimer therapeutic agent
11/18/2010US20100292145 Methods of regulating apoptosis
11/18/2010US20100292132 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
11/18/2010US20100292129 Methods and Compositions for Enhancing Proteasome Activity
11/18/2010US20100291628 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
11/18/2010US20100291242 Antagonist against tolerance to anticancer drugs
11/18/2010US20100291236 Osmium compounds
11/18/2010US20100291228 Scavenger of in vivo harmful reactive oxygen species and/or free radicals
11/18/2010US20100291218 Immunomodulatory compositions, formulations, and methods for use thereof
11/18/2010US20100291194 Compositions and Methods for Inhibiting Expression of a Mutant Gene
11/18/2010US20100291193 Immunogenic compositions comprising progastrin and uses thereof
11/18/2010US20100291191 Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
11/18/2010US20100291189 Method for producing a membrane protein
11/18/2010US20100291179 Composite biomaterial for controlled release of active ingredients
11/18/2010US20100291171 Hyaluronic acid derivatives obtained via "click chemistry" crosslinking
11/18/2010US20100291156 Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
11/18/2010US20100291127 Tumor associated antigen peptides and use of same as anti-tumor vaccines
11/18/2010US20100291126 Protein showing enhanced expression in cancer cells
11/18/2010US20100291125 Eta-1 gene and methods for use
11/18/2010US20100291124 Extracellular serine protease
11/18/2010US20100291121 Tumour-Specific Animal Proteins
11/18/2010US20100291118 Class of Gamma Delta T Cells Activators and Use Thereof
11/18/2010US20100291113 Treatment of Proliferative Disorders Using Antibodies to PSMA
11/18/2010US20100291112 Recombinant, Single-Chain, Trivalent Tri-Specific or Bi-Specific Antibody Derivatives
11/18/2010US20100291111 Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation
11/18/2010US20100291109 Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
11/18/2010US20100291108 Antibodies to irem-1
11/18/2010US20100291105 Agent for the treatment of malignant diseases
11/18/2010US20100291103 Polypeptides, antibody variable domains and antagonists
11/18/2010US20100291102 Therapeutic Agent
11/18/2010US20100291099 Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
11/18/2010US20100291096 Therapeutic peptides for the treatment of metatstatic cancer
11/18/2010US20100291094 Nucleic acid encoding 238p1b2 useful in detecting cancer
11/18/2010US20100291091 Cancer associated gene ly6k
11/18/2010US20100291089 Ligand of regulating immune response, and use thereof in treating an immune response-related disease
11/18/2010US20100291087 Method of treating fibrproliferative disorders
11/18/2010US20100291086 Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
11/18/2010US20100291077 Methods and Compositions for Modulating ERBB2 Activity
11/18/2010US20100291075 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies
1 ... 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 ... 2211